330 related articles for article (PubMed ID: 6097235)
1. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
[TBL] [Abstract][Full Text] [Related]
2. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
3. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
4. Transient concentrations and agonist potency of PGH2 in platelet activation by endogenous arachidonate.
Hornberger W; Patscheke H
Eicosanoids; 1989; 2(4):241-8. PubMed ID: 2517034
[TBL] [Abstract][Full Text] [Related]
5. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man.
Gresele P; Deckmyn H; Arnout J; Lemmens J; Janssens W; Vermylen J
Lancet; 1984 May; 1(8384):991-4. PubMed ID: 6143969
[TBL] [Abstract][Full Text] [Related]
6. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
Parise LV; Venton DL; Le Breton GC
J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
[TBL] [Abstract][Full Text] [Related]
7. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
Yin K; Halushka PV; Yan YT; Wong PY
J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
[TBL] [Abstract][Full Text] [Related]
8. Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat.
Dyson MC; Bellan JA; Minkes RK; Beckerman RC; Wegmann MJ; Braquet P; McNamara DB; Kadowitz PJ
J Pharmacol Exp Ther; 1990 Dec; 255(3):1320-7. PubMed ID: 2175802
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
10. Influence of trapidil derivatives on arachidonic acid- and prostaglandin endoperoxide analogue- induced platelet aggregation and thromboxane A2 formation.
Heinroth I; Block HU; Mest HJ
Biomed Biochim Acta; 1984; 43(8-9):S389-92. PubMed ID: 6440555
[TBL] [Abstract][Full Text] [Related]
11. Antiaggregatory effects of thromboxane receptor antagonists in vivo.
Darius H; Lefer AM
Thromb Res; 1985 Dec; 40(5):663-75. PubMed ID: 2935972
[TBL] [Abstract][Full Text] [Related]
12. Effect of trimetoquinol analogs for antagonism of endoperoxide/thromboxane A2-mediated responses in human platelets and rat aorta.
Mukhopadhyay A; Navran SS; Amin HM; Abdel-Aziz SA; Chang J; Sober DJ; Miller DD; Feller DR
J Pharmacol Exp Ther; 1985 Jan; 232(1):1-9. PubMed ID: 3855323
[TBL] [Abstract][Full Text] [Related]
13. Effects of methylprednisolone and hydrocortisone on aggregation of rabbit platelets induced by arachidonic acid and other aggregating substances.
Glass F; Lippton H; Kadowitz PJ
Thromb Haemost; 1981 Dec; 46(4):676-9. PubMed ID: 6800048
[TBL] [Abstract][Full Text] [Related]
14. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
[TBL] [Abstract][Full Text] [Related]
15. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
16. Effects of endogenous and synthetic prostanoids, the thromboxane A2 receptor agonist U-46619 and arachidonic acid on [3H]-noradrenaline release and vascular tone in rat isolated kidney.
Rump LC; Schollmeyer P
Br J Pharmacol; 1989 Jul; 97(3):819-28. PubMed ID: 2503228
[TBL] [Abstract][Full Text] [Related]
17. Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha.
Krauss AH; Woodward DF; Gibson LL; Protzman CE; Williams LS; Burk RM; Gac TS; Roof MB; Abbas F; Marshall K; Senior J
Br J Pharmacol; 1996 Mar; 117(6):1171-80. PubMed ID: 8882612
[TBL] [Abstract][Full Text] [Related]
18. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.
Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV
J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275
[TBL] [Abstract][Full Text] [Related]
19. Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets.
di Minno G; Bertelé V; Bianchi L; Barbieri B; Cerletti C; Dejana E; de Gaetano G; Silver MJ
Thromb Haemost; 1981 Apr; 45(2):103-6. PubMed ID: 6266066
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
Tymkewycz PM; Jones RL; Wilson NH; Marr CG
Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
